RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)

Recruiting

Phase 3

RGX-121RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)

Sponsor:

REGENXBIO Inc.

Code:

NCT07236606

Conditions

MPS II

Hunter Syndrome (MPS II)

Eligibility Criteria

Sex: Male

Age: 0 - 5

Healthy Volunteers: Not accepted

Interventions

RGX-121-3102

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-30. This information was provided to ClinicalTrials.gov by REGENXBIO Inc. on 2025-11-26.